Organon & Co | OGN - Equity Capital And Reserves


Organon & Co reported $906M in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
Bristol-Myers Squibb USD 18.55B 1.06B Sep/2025
Celltrion KRW 16.7T 182.36B Sep/2025
Cspc Pharmaceutical CNY 33.18B 71.46M Dec/2025
Deva Holding AS TRY 5.79B 604.07M Sep/2023
Dianthus Therapeutics USD 493.4M 53.05M Dec/2025
Divis Laboratories Ltd INR 154.13B 4.44B Sep/2025
Gilead Sciences USD 22.62B 1.16B Dec/2025
Glaxosmithkline GBP 22.06B 360M Dec/2025
Kangmei Pharma CNY 7.22B 504.3M Sep/2025
Knight Therapeutics CAD 767.27M 480K Dec/2025
Laboratorios Farma EUR 539.39M 22.74M Dec/2023
Malin Corporation EUR 193.2M 75M Dec/2024
Medical Developments International AUD 54.77M 335K Dec/2025
Merck USD 51.85B 2.79B Sep/2025
Neuren Pharmaceuticals AUD 338.45M 15.18M Dec/2025
Novartis USD 46.13B 1.8B Dec/2025
Organigram Holdings CAD 369.46M 20.33M Dec/2025
Organon & Co USD 906M 173M Sep/2025
Ovoca Bio EUR 1.26M 7.41M Jun/2025
Pharma Mar EUR 251.83M 54.32M Dec/2025
Qiagen NV USD 3.78B 128.73M Dec/2025
Sartorius EUR 2.67B 9.9M Sep/2025
Sino Biopharmaceutical CNY 34B 1.48B Jun/2025
Tilray USD 1.58B 39.08M Sep/2025
Zealand Pharma A/S 14.83B 331.99M Dec/2025